Tags : Tetra Therapeutics

M&A

Shionogi to Acquire Tetra Therapeutics for ~$500M

Shots: Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770 In 2018, the two companies collaborated and in 2020 expand their alliance to develop and commercialize […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 09-13, 2020)

1. I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19 Published: Mar 13, 2020 | Tags: I-Mab, Initiate, Development, TJM2, Treating, Cytokine Release Syndrome, COVID-19 2. EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head […]Read More